The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial
Abstract
Purpose: This randomized, 2 × 2 factorial study compared a semimonthly (LVFU2) with a monthly (FULV) regimen of fluorouracil and leucovorin and 24 versus 36 weeks of each regimen as adjuvant treatment of patients with stage II (Dukes’ B2) and III (Dukes’ C) colon cancer. Patients and Methods: LVFU2 was administered semi-monthly for 2 consecutive days as dl- or l-leucovorin (200 or 100 mg/m 2, respectively) as a 2-hour infusion, followed by a 400 mg/m 2 FU bolus and 600 mg/m 2 of FU as a 22-hour continuous infusion. FULV was administered monthly for 5 consecutive days as a 15-minute infusion of dl- or l-leucovorin, followed by 400 mg/m 2 of FU as a 15-minute infusion. Results: A total of 905 patients were randomly assigned. The median follow-up was 41 months. Disease-free survival was similar between the LVFU2 and FULV groups (127 v 124 events; hazard ratio [HR] = 1.04; P = .74) and between 24 and 36 weeks of therapy (128 v 123 events; HR = 0.94; P = .63). Analysis of overall survival showed a slight excess in the number of deaths in LVFU2 compared with FULV (73 v 59), but this difference was not statistically significant (HR = 1.26; 95% confidence interval, 0.90 to 1.78; P = .18). The most commonly observed grade 3 to 4 toxicities were neutropenia, diarrhea, and mucositis. Toxicities were significantly lower in the LVFU2 group (all toxicities, P < .001). Conclusion: Our data confirm that LVFU2 is less toxic than FULV. At a median follow-up of 41 months, no statistically significant difference could be detected in disease-free or overall survival between the treatment groups or treatment durations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citationDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,256
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
(1995) · The Lancet · doi:10.1016/s0140-6736(95)90696-7 · Cited by 1,066
de Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouché, O., Etienne, P. L., Morvan, F., Louvet, C., Guillot, T., François, E., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.808 · Cited by 908
Self-citationPoon, M. A., O'Connell, M. J., Moertel, C. G., Wieand, H. S., Cullinan, S. A., Everson, L. K., Krook, J. E., Mailliard, J. A., Laurie, J. A., & Tschetter, L. K. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1407 · Cited by 887
Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., & Fryer, J. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.425 · Cited by 773
O'Connell, M. J., Mailliard, J. A., Kahn, M. J., Macdonald, J. S., Haller, D. G., Mayer, R. J., & Wieand, H. S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.246 · Cited by 585
Petrelli, N., Douglass, H. O., Herrera, L., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., & Muggia, F. M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1419 · Cited by 556
Mamounas, E., Wieand, S., Wolmark, N., Bear, H. D., Atkins, J. N., Song, K., Jones, J., & Rockette, H. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1349 · Cited by 531
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3537 · Cited by 495
Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., Bear, H. D., Atkins, J. N., Dimitrov, N. V., Glass, A. G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3553 · Cited by 493
Petrelli, N., Herrera, L., Rustum, Y., Burke, P., Creaven, P., Stulc, J., Emrich, L. J., & Mittelman, A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1559 · Cited by 450
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer
(1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1356 · Cited by 444
Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
O'Connell, M. J., Laurie, J. A., Kahn, M., Fitzgibbons, R. J., Erlichman, C., Shepherd, L., Moertel, C. G., Kocha, W. I., Pazdur, R., Wieand, H. S., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.295 · Cited by 417
Machover, D., Goldschmidt, E., Chollet, P. J. M., Metzger, G., Zittoun, J., Marquet, J., Vandenbulcke, J., Misset, J. L., Schwarzenberg, L., & Fourtillan, J. B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.5.685 · Cited by 397
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
Sobrero, A. F., Aschele, C., & Bertino, J. R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.368 · Cited by 336
Buroker, T. R., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Mailliard, J. A., Schaefer, P. L., Levitt, R., Kardinal, C. G., & Gesme, D. H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.14 · Cited by 311
Mundy, G. R., Yoneda, T., & Hiraga, T. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90263-5 · Cited by 121
Should Dukes' B patients receive adjuvant therapy? A statistical perspective
Buyse, M. E., & Piedbois, P. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90247-7 · Cited by 109
Self-citationWolmark, N., Smith, R. P., Fisher, B., Bryant, J., Hyams, D. M., Atkins, J., Dimitrov, N. S., Oishi, R. H., Prager, D., Fehrenbacher, L., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.23.1810 · Cited by 101
Budd, G. T., Fleming, T. R., Bukowski, R. M., McCracken, J. D., Rivkin, S. E., OʼBryan, R. M., Balcerzak, S. P., & Macdonald, J. S. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.2.272 · Cited by 81
André, T., Colin, P., Louvet, C., Gamelin, E. C., Bouché, O., Achille, E., Colbert, N., Boaziz, C., Piedbois, P., Tubiana-Mathieu, N., et al. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90250-7 · Cited by 21
Self-citation
Cited by
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Self-citationAndré, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,277
Self-citationSchmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
Metadata
- Authors
- André, T., Colin, P., Louvet, C., Gamelin, E., Bouche, O., Achille, E., Colbert, N., Boaziz, C., Piedbois, P., Tubiana-Mathieu, N., Boutan-Laroze, A., Flesch, M., Buyse, M., & de Gramont, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-08-01
- Volume
- 21
- Issue
- 15
- Pages
- 2896-2903
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2137408681
- Cited by
- 262
- References
- 25
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.